MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
February 14, 2022 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
February 03, 2022 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
November 03, 2021 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 03, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results
November 02, 2021 16:01 ET
|
MacroGenics, Inc.
Investigational New Drug (IND) application submitted for MGD024, a next generation DART® molecule targeting CD123 and CD3 for AMLU.S. Food & Drug Administration (FDA) approves MacroGenics’ GMP...
MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call
October 26, 2021 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
September 16, 2021 02:45 ET
|
MacroGenics, Inc.
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor...
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
September 16, 2021 02:45 ET
|
MacroGenics, Inc.
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor...
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
September 12, 2021 19:00 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer
September 07, 2021 16:30 ET
|
MacroGenics, Inc.
Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumabOS was greater with MARGENZA plus chemotherapy in exploratory subgroups of...
MacroGenics to Participate in Upcoming Investor Conferences
September 02, 2021 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...